Bisabolol

Bisabolol (α-Bisabolol / Levomenol): A Comprehensive Reference

1. Identity

Chemical and Botanical Names

Bisabolol, or more formally α-(−)-bisabolol, is also known as levomenol and is a natural monocyclic sesquiterpene alcohol. It has the chemical formula C₁₅H₂₆O. Its molecular weight is 284.7 g/mol, with a density of 0.927–0.935 g/cm³. As a sesquiterpene alcohol, it is soluble in ethanol, fatty alcohols, and glycerol esters, but insoluble in water and glycerine.

Natural Sources

It is a colorless viscous oil that is the primary constituent of the essential oil from German chamomile (Matricaria recutita) and Myoporum crassifolium. In addition to cannabis and hops, this unsaturated monocyclic sesquiterpene alcohol is found in essential oils from the candeia tree, salvia, Plinia, Eremanthus, and cat's claw. It is the main constituent in some essential oils; for instance, more than 80% of the essential oil from Myoporum crassifolium (a figwort from the Pacific islands) is bisabolol. Bisabolol was sometimes the second most abundant terpene (17%) out of 200 analyzed samples of cannabis, and is present in hops at levels of up to 16%. Additional documented sources include sage (Salvia runcinata), anyme wood oil (Myoporum crassifolium), and negramina (Siparuna guianensis).

German chamomile contains 0.24%–1.9% volatile oil, composed of a variety of separate oils. Approximately 120 secondary metabolites have been identified in chamomile, including 28 terpenoids and 36 flavonoids. α-Bisabolol occurs at concentrations of 10–25% of the chamomile essential oil.

Stereochemistry and Enantiomers

The enantiomer, α-(+)-bisabolol, is also found in nature but is rare. Synthetic bisabolol is usually a racemic mixture of the two, designated α-(±)-bisabolol. Unlike synthetic bisabolol, which contains both the D-alpha bisabolol (inactive form) and the L-alpha bisabolol (natural, active form), plant-based bisabolol contains only the active form. The structurally related compound, β-bisabolol (CAS 15352-77-9), differs in the positioning of the tertiary alcohol functional group.

Extraction and Commercial Forms

Bisabolol is obtained by fractional distillation of the essential oil of candeia (Eremanthus erythropappus), a small tree from the Brazilian savannah, followed by purification. It is also extracted from German chamomile essential oil via steam distillation. It is the terpenoid responsible for the distinctive aroma of chamomile flowers, and when isolated its scent has been likened to apples, sugar, and honey. Bisabolol has a weak sweet floral aroma described as fruity, nutty, and coconut.

It is a common additive in many consumer products, including moisturizing creams and ointments, lotions, cleansers, sunscreens, antiperspirants, and makeup products. Bisabolol's low toxicity has allowed its inclusion by the U.S. Food and Drug Administration (FDA) in the list of Generally Recognized As Safe (GRAS) compounds, promoting its use as an active ingredient in numerous cosmetic and dermatological formulations.

2. Traditional and Historical Use

European Herbal Medicine

Since ancient times, German chamomile has been used in both folk and official medicine. Matricaria chamomilla L. belongs to the family Asteraceae and is an essential oil-containing medicinal herb widely known and used in Europe, Asia, and the Americas. Chamomile is usually consumed as a tea or tincture. Its essential oil and tincture are the components of several traditional and homeopathic medicinal preparations. The galenic preparations of German chamomile have been used to treat mild skin diseases, inflammation, and spasms, and have also been reported to have anxiolytic and sedative effects. They are also recorded as useful for treating flatulence, colic, ulcers, wounds, hysteria, and depression.

Chamomile has a long history of use in European herbal medicine for its calming effects on both the body and skin. In its natural state, chamomile contains bisabolol, which was historically used to soothe burns, reduce redness, and promote the healing of minor wounds.

South American Traditional Use

In South America, the candeia tree served as a natural source of bisabolol, and indigenous communities historically used its extract to treat cuts, skin infections, and inflammation.

Ayurvedic, Unani, and Other Systems

Matricaria chamomilla L. is widely used in traditional medicine to treat many kinds of diseases, including infections, neuropsychiatric, respiratory, gastrointestinal, and liver disorders. It is also used as a sedative, antispasmodic, antiseptic, and antiemetic.

Matricaria chamomilla has been used in folk medicine as a plant-based remedy for many ailments in ancient times, a tradition that has survived to the present day. While bisabolol was not isolated as a pure compound until more recently, bisabolol was formally isolated from the essential oil of the chamomile flower (Chamomilla recutita) in 1951, where it is present in large quantities.

3. Key Constituents, Chemistry, and Mechanisms of Action

Chemical Classification and Co-occurring Compounds

α-Bisabolol is a naturally derived monocyclic sesquiterpene, abundantly present in German chamomile (Matricaria recutita) and various other aromatic plants, and is also increasingly accessible via metabolic engineering platforms. When present in chamomile essential oil, bisabolol co-occurs with chamazulene, apigenin, and bisabolol oxides A and B, though these are distinct compounds.

Bioavailability and Pharmacokinetics

Bioavailability is governed by its lipophilic nature (logP ≈ 4.0–4.5), meaning percutaneous absorption is favorable for topical applications, with in vitro skin penetration studies showing meaningful dermal uptake through stratum corneum partitioning. Oral bioavailability data in humans is limited, but animal studies suggest hepatic first-pass metabolism is significant. The physicochemical profile and ADMET characteristics of α-bisabolol suggest high gastrointestinal absorption and minimal P-glycoprotein and CYP450 interactions, which validate its drug-like potential.

Anti-inflammatory Mechanisms

In LPS-stimulated RAW264.7 macrophage cells, (−)-α-bisabolol inhibited lipopolysaccharide-induced production of nitric oxide (NO) and prostaglandin E₂ (PGE₂); expression of COX-2 and inducible nitric oxide synthase (iNOS) genes was also reduced, as evidenced by Western blot and luciferase reporter assays. These results indicate that (−)-α-bisabolol exerts anti-inflammatory effects by downregulating expression of iNOS and COX-2 genes through inhibition of NF-κB and AP-1 (ERK and p38) signaling.

The anti-inflammatory effect of α-bisabolol was further elucidated through α-bisabolol-induced suppression of ERK and p38 phosphorylation, mediated by inhibition of NF-κB and activator protein-1 (AP-1) signaling cascades. Studies have also reported a decrease in TNF-α, IL-6, IL-1β levels and iNOS and COX-2 activities, concurrently with increased IL-10.

In colitis models, α-bisabolol decreased the phosphorylation of activated MAPK signaling and NF-κB proteins, and enhanced colon epithelial PPAR-γ transcription factor expression. PPAR-α and β/δ expression was not altered, indicating α-bisabolol is a specific stimulator of PPAR-γ. In silico docking analysis revealed that α-bisabolol has a strong binding affinity for the PPAR-γ binding site. PPAR-γ forms a complex with the NF-κB subunit p65, leading to alteration of proinflammatory gene expression, thereby attenuating expression of cytokines including IL-1β, COX-2, IL-6, IL-8, TNF-α, IFNγ, iNOS, and chemokines in colonic epithelial cells.

Antioxidant Mechanisms

The antioxidant mechanism of α-bisabolol is mainly associated with the reduction of reactive oxygen/nitrogen species (ROS/RNS), malondialdehyde (MDA), and glutathione (GSH) depletion, myeloperoxidase (MPO) activity, and augmentation of superoxide dismutase (SOD) and catalase (CAT) activities.

Anticancer Mechanisms

Mechanistically, the anticancer profile of α-bisabolol arises from the induction of mitochondrial apoptosis, disruption of PI3K/Akt/FAK/BRAF pathways, modulation of lipid-raft-associated Bid protein, and dysregulation of autophagy. Via gas chromatography mass spectrometry, α-bisabolol was shown to be adsorbed into flotillin-rich structures known as lipid rafts. Bid, a member of the Bcl-2 pro-apoptotic family proteins, was also present in the flotillin-enriched fraction, referring to α-bisabolol-induced movement of Bid to lipid raft-rich membrane regions. Surface Plasmon Resonance analysis confirmed that α-bisabolol interacts directly with Bid. The compound's apoptotic action is therefore mediated through this interaction with Bid protein.

Analgesic / Antinociceptive Mechanisms

A screen of eight commercially available terpenes revealed that alpha-bisabolol mediated partial but significant inhibition of Cav3.2 channels expressed in tsA-201 cells, as well as native T-type channels in mouse dorsal root ganglion neurons. Alpha-bisabolol inhibited human recombinant Cav3.2 channels with an IC₅₀ of 7.7 ± 1.8 μM with maximal inhibition of approximately 25%. While no effect was observed on activation of Cav3.2 channels, the terpene shifted the steady-state inactivation curve toward more hyperpolarized potentials, contributing to inhibition of channel activity.

Anti-apoptotic vs. Pro-apoptotic Duality

In non-cancerous cells subjected to stress, upregulation of bcl-2 expression and suppression of bax, P53, APAF-1, caspase-3, and caspase-9 activity indicates anti-apoptotic effects of α-bisabolol. This protective anti-apoptotic profile in normal tissues contrasts with the pro-apoptotic profile observed selectively in malignant cells, discussed further below.

4. Scientific Evidence by Area of Use

4.1 Skin Inflammation, Dermatitis, and Wound Healing

A clinical investigation reported that the use of a topical formulation containing α-bisabolol improved inflammatory status and showed a reduction in the severity of eczema in treated children. In a murine model using DNCB-induced atopic dermatitis in BALB/c mice, topical bisabolol treatment reduced AD-like symptoms and the release of IL-4 without IgE production. Histopathological examination revealed that bisabolol reduced epidermal thickness and inhibited mast cells in the AD-like lesion skin. Oral administration of bisabolol effectively and dose-dependently suppressed mast cell-mediated passive cutaneous anaphylaxis.

α-Bisabolol has been demonstrated to exert a cicatrizant (wound-closing) effect in mice, speculated to be attributed to the 1-methylcyclohexene and tertiary hydroxyl structural moieties. It was found that although α-bisabolol is a less potent cicatrizant than taspine, it is notably less cytotoxic.

A topical cream containing 0.5% bisabolol applied for 8 weeks was shown to have a strong whitening effect on UV-exposed pigmented skin when compared to a control formulation without the ingredient. The Cosmetic Ingredient Review (CIR) Panel noted a study reporting possible lightening of the skin after induction of pigmentation by ultraviolet light (0.5% bisabolol topically daily for 8 weeks), though they determined this study did not warrant a change in their safety conclusions.

Evidence characterization: Human evidence in dermatology is limited primarily to small clinical studies, case reports, and in-vitro/in-vivo animal models. The evidence is consistent in direction but generally preliminary. No large-scale randomized controlled trials (RCTs) specifically on isolated bisabolol in skin conditions have been identified.

4.2 Anti-inflammatory Activity (Preclinical)

Molecular docking and dynamic analysis revealed that α-bisabolol interacts with PPAR-γ, a nuclear receptor protein highly expressed in the colon epithelium. Treatment with α-bisabolol in DSS-administered mice significantly reduced Disease Activity Index (DAI), myeloperoxidase (MPO) activity, and colonic length, and protected the microarchitecture of the colon. α-Bisabolol treatment also reduced expression of proinflammatory cytokines IL-6, IL-1β, TNF-α, and IL-17A at protein and mRNA levels.

One study evaluated the in vitro anti-inflammatory and utero-relaxant effect of α-bisabolol on the pregnant human myometrium. Samples from pregnant human myometrium were used in functional tests to evaluate the inhibitory effect of α-bisabolol (560, 860, 1,200, and 1,860 μM) on spontaneous myometrial contractions. Intracellular cyclic adenosine monophosphate (cAMP) levels generated in response to α-bisabolol in human myometrial homogenates were measured by ELISA. The anti-inflammatory effect was determined through measurement of TNF-α, IL-1β, and the anti-inflammatory cytokine IL-10 in pregnant human myometrial explants stimulated with LPS.

Evidence characterization: Anti-inflammatory evidence in the gastrointestinal and uterine context is predominantly preclinical (in vitro and animal models). One in vitro study used actual human tissue. Clinical trials in human inflammatory disease are lacking.

4.3 Anticancer Activity

α-Bisabolol inhibits growth and induces apoptosis in several malignancies, including glioblastoma, acute leukemia, and pancreatic, prostatic, breast, and liver cancer, based on preclinical evidence.

Glioma: α-Bisabolol was found to have a strong time- and dose-dependent cytotoxic effect on human and rat glioma cells. After 24 hours of treatment with 2.5–3.5 μM α-bisabolol, the viability of these cells was reduced by 50% with respect to untreated cells. The viability of normal rat glial cells was not affected by treatment with α-bisabolol at the same concentrations. Glioma cells treated with high concentrations of α-bisabolol (10 μM) resulted in 100% cell death.

Leukemia: Ex vivo blasts from 42 acute leukemias (14 Philadelphia-negative and 14 Philadelphia-positive B acute lymphoid leukemias, and 14 acute myeloid leukemias) were tested for their sensitivity to α-bisabolol in 24-hour dose-response assays. The study shows that α-bisabolol enters acute leukemic cells, where it disrupts the mitochondrial membrane potential and triggers apoptosis. α-Bisabolol appears to be a much more effective agent in some Ph-B-ALL cells than in other types of acute leukemias, at dosages that spare normal leukocytes and hematopoietic stem cells.

CML / BCR-ABL+ leukemia: α-Bisabolol was demonstrated to synergistically enhance the apoptotic effects of imatinib and nilotinib in BCR-ABL+ cells through induction of mitochondrial membrane damage, at least partially via mPTP activation and irreversible opening. The use of this drug combination allowed reduction of imatinib and nilotinib doses up to 9-fold to obtain the same cytotoxic effect. These findings suggest that α-bisabolol and TKI could represent a viable combination treatment for BCR-ABL+ leukemias.

Pancreatic cancer: α-Bisabolol was reported to inhibit proliferation, invasiveness, and motility of pancreatic cancer cells both in vitro and in vivo. In subsequent work, 22 derivatives of α-bisabolol were designed and synthesized. Two derivatives (4 and 5) had more potent inhibitory effects on the proliferation of pancreatic cancer cells than did α-bisabolol itself. A further 15 derivatives were synthesized; among them, derivative 5 had the strongest inhibitory effect and reduced the proliferation of various pancreatic cancer cell lines, including KLM1, Panc1, and KP4.

Evidence characterization: All anticancer evidence to date for α-bisabolol is preclinical — derived from in vitro cell culture experiments and in vivo animal models. The multi-protein target engagement and predicted activity spectrum of α-bisabolol has been discussed using in silico tools (SwissTargetPrediction and PASS), which aligns with experimental anticancer results in leukemia, pancreatic, lung, and glioblastoma models. No human clinical trials of α-bisabolol as an anticancer agent have been published. Evidence is promising but cannot be extrapolated to clinical use at this time.

4.4 Analgesic and Antinociceptive Effects

Systemic (oral) α-bisabolol showed efficacy in a model of visceral inflammation, in the second phase of the formalin test in mice, and in carrageenan-induced inflammation. The authors concluded that its effect was mediated primarily by an anti-inflammatory action rather than a direct effect on the nervous system.

When delivered intrathecally, α-bisabolol inhibited nocifensive responses in mice that had received an intraplantar injection of formalin, showing greater efficacy than camphene. Both terpenes reduced thermal hyperalgesia in mice injected with Complete Freund's adjuvant. This effect was independent of sex, and absent in Cav3.2 null mice, indicating these compounds mediate their analgesic properties by acting on Cav3.2 channels.

Alpha-bisabolol has demonstrated analgesic effects in inflammatory pain models by blocking Cav3.2 calcium channels. As the pain pathway overlaps with mechanisms for itch, and because Cav3.2 channels have been associated with itch, researchers have investigated potential anti-itch effects of these terpenes. Both compounds significantly reduced scratching in the histaminergic itch model, whether administered subcutaneously or intraperitoneally.

Evidence characterization: All analgesic evidence is from preclinical animal models and cell-based studies. No human clinical analgesic trials have been identified.

4.5 Gastrointestinal and Gastroprotective Effects

Preclinical findings demonstrate that bisabolol has the potential to improve disease activity and rescue colonic tissues from damage by inhibiting oxidative stress, lipid peroxidation, and inflammation. The findings are suggestive of benefits in IBD treatment and substantiate usefulness in colitis management, along with gastroprotective effects in gastric ulcer.

Evidence characterization: Gastrointestinal evidence is limited to in vitro and animal models. No human clinical trials assessing bisabolol for gastrointestinal disease have been identified.

4.6 Neuroprotective Effects

In a rotenone-induced rat model of Parkinson's disease, bisabolol treatment salvaged dopaminergic neurons, attenuated microglia and astrocyte activation, inhibited induction of inflammatory mediators and proinflammatory cytokines, and reduced expression of pro-apoptotic markers. The results were suggestive of neuroprotective effects through antioxidant, anti-inflammatory, and anti-apoptotic properties.

The neuroprotective action of (−)-α-bisabolol was evaluated by testing antioxidant, anti-aggregation, and anti-apoptotic activities, as well as acetylcholinesterase (AChE) inhibitory potential, using amyloid β-protein (Aβ)-induced neurotoxicity in Neuro-2a cells. Cells pre-treated with (−)-α-bisabolol showed improved potential to scavenge reactive oxygen and nitrogen species, restored mitochondrial membrane potential loss, and prevented induced apoptosis. AChE was reduced significantly in cells pretreated with α-bisabolol. In another study, α-bisabolol was reported to prevent the formation of Aβ oligomers and to disaggregate already formed mature fibrils using an Aβ₂₃₋₃₅-induced neurotoxicity model.

Recent data suggest that oral administration of α-bisabolol may provide neuroprotection through decreased neurodegeneration and neuroinflammation, as well as cognitive improvement.

Evidence characterization: All neuroprotective evidence is from cell culture and animal models. No human clinical neurological trials have been identified. Evidence is preliminary.

4.7 Antimicrobial and Antifungal Activity

α-Bisabolol, which is nontoxic and nonirritating to the skin, possesses antimycotic and antibacterial effects, and is a potent inhibitor of fungi, Candida albicans, and gram-positive bacteria. The antifungal activity of α-bisabolol has been evaluated on Aspergillus fumigatus species. The antimicrobial effect is mediated by inhibiting the viability of infected cells.

Evidence characterization: Antimicrobial evidence is in vitro. Clinical antimicrobial trials have not been identified.

4.8 Skin Penetration Enhancement

Bisabolol is also demonstrated to enhance the percutaneous absorption of certain molecules and has found use as a penetration enhancer: an agent used in topical formulations to increase the substances' propensity for absorption beneath the skin. One study using cadaver skin demonstrated that bisabolol can enhance the penetration of 5-fluorouracil. An in vitro study demonstrated that bisabolol is a penetration enhancer and appeared to have synergistic action with propylene glycol.

5. Body Systems and Health Areas

• Integumentary system (skin): Anti-inflammatory, soothing, wound-healing (cicatrizant), anti-eczema, depigmenting/whitening, penetration enhancement. Evidence ranges from in vitro to small clinical.
• Immune system: Inhibition of NF-κB, MAPK, AP-1; reduction of proinflammatory cytokines (TNF-α, IL-1β, IL-6, IL-17A); activation of PPAR-γ. Evidence: in vitro and animal models.
• Gastrointestinal system: Gastroprotective, anti-colitis, anti-ulcer. Evidence: animal models and in vitro.
• Nervous system: Neuroprotection, dopaminergic neuron preservation, AChE inhibition, anti-amyloid aggregation. Evidence: cell culture and animal models only.
• Pain pathways: Cav3.2 T-type calcium channel inhibition; antinociceptive and anti-itch effects. Evidence: animal and cell models.
• Oncology: Pro-apoptotic in cancer cell lines (glioblastoma, leukemia, pancreatic, breast, liver, lung). Evidence: in vitro and in vivo xenograft models; no human trials.
• Cardiovascular system: Cardioprotective properties have been demonstrated in experimental studies. Evidence: animal models.

6. Dosage Forms and Reported Dosages

Topical (Cosmetic/Dermatological)

α-Bisabolol is used in a wide range of cosmetic formulations as a skin conditioning agent at low concentrations ranging from 0.001% in lipstick to 1% in underarm deodorants. The typical concentration of bisabolol in cosmetic formulations is between 0.1–0.2%. In a clinical study, a commercial product containing 0.1% bisabolol was negative for sensitization. A topical cream containing 0.5% bisabolol applied for 8 weeks was evaluated for skin-whitening effects on UV-exposed pigmented skin.

Oral (Preclinical Only)

No established human doses exist for oral use; preclinical studies have used 25 mg/kg in rats. In the pro-apoptotic leukemia ex-vivo models, α-bisabolol was effective with an IC₅₀ of 14 ± 5 μM in a substantial proportion of Ph-B-ALL cells. In glioma cell studies, after 24 hours of treatment with 2.5–3.5 μM α-bisabolol, the viability of cancer cells was reduced by 50%.

In Vitro / Receptor Studies

In the uterine anti-inflammatory study, α-bisabolol was evaluated at concentrations of 560, 860, 1,200, and 1,860 μM on spontaneous myometrial contractions. In Cav3.2 channel inhibition, both terpenes inhibited peak current amplitude with IC₅₀s in the low micromolar range.

7. Safety Considerations and Interactions

Regulatory Status and General Toxicology

The FDA has categorized (−)-α-bisabolol as "Generally Recognized As Safe (GRAS)" because of its low toxicity as well as its antimicrobial properties. In reviewing the safety of bisabolol, the Cosmetic Ingredient Review (CIR) Expert Panel was satisfied that the results of oral and dermal toxicity, mutagenicity, reproductive/developmental toxicity, photosensitization, and clinical sensitization studies cited show little toxicity at levels expected in cosmetic formulations. A 28-day dermal toxicity study determined a NOAEL (No Observed Adverse Effect Level) of 200 mg/kg/day, which corresponded to a 4% bisabolol solution (87.5% pure).

Acute oral LD₅₀ values include 15.1 ml/kg in mice, and 14.9 and 15.6 ml/kg in male and female rats, respectively. Bisabolol was relatively nontoxic in acute oral studies in rats, dogs, and monkeys. Short-term oral exposure using rats did produce inflammatory changes in several organs, and reduced body weight and increased liver weights relative to body weight in dogs.

Genotoxicity and Reproductive Toxicity

Bisabolol was negative in the Ames test and the chromosome aberration assay using Chinese hamster cells. Bisabolol was negative in bacterial and mammalian genotoxicity tests, and it did not produce reproductive or developmental toxicity. Bisabolol was also negative in a dermal photosensitization study with guinea pigs and was not teratogenic in an oral dose study.

Sensitization and Contact Dermatitis

No evidence of sensitization or photosensitization was found in the 1999 CIR safety assessment. However, contact dermatitis from bisabolol has been reported in Europe and is purported to occur in the United States. Patch testing with bisabolol-containing products or bisabolol may be useful in the work-up of patients with presumptive allergic contact dermatitis or potentially worsening atopic dermatitis. Available data demonstrate that α-bisabolol is a weak sensitizer, with a Weight of Evidence No Expected Sensitization Induction Level (WoE NESIL) of 5,500 μg/cm².

Penetration Enhancement: Formulary Caution

An in vitro study demonstrated that bisabolol is a penetration enhancer and appeared to have synergistic action with propylene glycol. The CIR Panel noted that bisabolol was used in baby lotions, and cautioned formulators to the possibility of increased absorption of other ingredients also contained in the formulation, especially those whose safety is based on their lack of dermal absorption.

Evidence Gaps

The effectiveness of α-bisabolol on human health is still a subject of investigation. More clinical studies are needed to gain in-depth insight into its beneficial properties on human health. Well-designed clinical trials are necessary to translate the promising preclinical findings into therapeutic applications for inflammatory conditions such as IBD. The large majority of pharmacological research — in oncology, neuroprotection, pain, gastroenterology, and systemic anti-inflammation — rests on in vitro or animal evidence, and human clinical data are sparse or absent outside of topical dermatological applications.

References

• Eddin LB, et al. "Health Benefits, Pharmacological Effects, Molecular Mechanisms, and Therapeutic Potential of α-Bisabolol." PMC, 2022.
• Ahmad et al. "Bisabolol as a natural anticancer agent: molecular insights and therapeutic potential in oncology." PubMed, 2025.
• Cavalieri E, et al. "alpha-Bisabolol, a nontoxic natural compound, strongly induces apoptosis in glioma cells." PubMed, 2004.
• Srivastava JK, et al. "Chamomile: A herbal medicine of the past with bright future." PMC, 2010.
• Jin BR, et al. "Inhibitory effects of (−)-α-bisabolol on LPS-induced inflammatory response in RAW264.7 macrophages." PubMed, 2011.
• Kaur M, et al. "α-Bisabolol Mitigates Colon Inflammation by Stimulating Colon PPAR-γ Transcription Factor: In Vivo and In Vitro Study." PMC, 2022.
• Ortiz MI, et al. "Anti-inflammatory and utero-relaxant effect of α-bisabolol on the pregnant human uterus." PMC, 2018.
• Bonifacio M, et al. "α-bisabolol Is an Effective Proapoptotic Agent against BCR-ABL+ Cells in Synergism with Imatinib and Nilotinib." PMC, 2012.
• Cavalieri E, et al. "Pro-apoptotic activity of α-bisabolol in preclinical models of primary human acute leukemia cells." PMC, 2011.
• Murata Y, et al. "The Anticancer Effects of Novel α-Bisabolol Derivatives Against Pancreatic Cancer." Anticancer Research, 2017.
• Weiss N, et al. "The terpenes camphene and alpha-bisabolol inhibit inflammatory and neuropathic pain via Cav3.2 T-type calcium channels." PMC, 2021.
• Hage-Sleiman R, et al. "The terpenes alpha-bisabolol and camphene modulate pruritus via an action on Cav3.2 T-type calcium channels." PMC, 2025.
• Rehman MU, et al. "α-Bisabolol, a Dietary Bioactive Phytochemical Attenuates Dopaminergic Neurodegeneration through Modulation of Oxidative Stress, Neuroinflammation and Apoptosis in Rotenone-Induced Rat Model of Parkinson's Disease." PMC, 2020.
• Hasan MM, et al. "α-Bisabolol, a Dietary Bioactive Terpene Attenuates Oxidative Stress and Inflammation in Colonic Mucosa of Acetic Acid-Induced Colitis in Rats." PMC, 2025.
• Lee SY, et al. "(−)-α-Bisabolol Alleviates Atopic Dermatitis by Inhibiting MAPK and NF-κB Signaling in Mast Cell." PMC, 2022.
• Farrag AM, et al. "In vitro and in silico neuroprotective evaluation of new biotransformation metabolites of (−)-α-bisabolol." PMC, 2025.
• Ielciu I, et al. "Phytochemical, Technological, and Pharmacological Study on the Galenic Dry Extracts Prepared from German Chamomile (Matricaria chamomilla L.) Flowers." PMC, 2024.
• El Mihyaoui A, et al. "Chamomile (Matricaria chamomilla L.): A Review of Ethnomedicinal Use, Phytochemistry and Pharmacological Uses." PMC, 2022.
• Ramazani E, et al. "Pharmacological and biological effects of alpha-bisabolol: An updated review of the molecular mechanisms." ScienceDirect, 2022.
• Cosmetic Ingredient Review (CIR) Expert Panel. "Safety Assessment of Bisabolol as Used in Cosmetics." CIR, 2015.
• Andersen FA. "Final Report on the Safety Assessment of Bisabolol." International Journal of Toxicology, 1999.
• Russell K, Jacob SE. "Bisabolol." Dermatitis, 2010. PubMed.
• Wikipedia. "Bisabolol." (for general structural/chemical cross-reference)